{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:56:53Z","timestamp":1785653813469,"version":"3.56.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005689","name":"G\u00f6teborgs L\u00e4kares\u00e4llskap","doi-asserted-by":"publisher","award":["18\/786051"],"award-info":[{"award-number":["18\/786051"]}],"id":[{"id":"10.13039\/501100005689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska Universitetssjukhuset","doi-asserted-by":"publisher","award":["Grants from the Swedish state, ALF agreement"],"award-info":[{"award-number":["Grants from the Swedish state, ALF agreement"]}],"id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005751","name":"Stiftelsen Edit Jakobssons Donationsfond","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100005751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2022,7,13]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (N<jats:sub>CORE<\/jats:sub>) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFN\u03b2) and\/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFN\u03b2 treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV N<jats:sub>CORE<\/jats:sub> as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV N<jats:sub>CORE<\/jats:sub> IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV N<jats:sub>CORE<\/jats:sub> IgG declined, compared with the relatively stable levels noted during prior IFN\u03b2 treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10\/144 controls were EBV seronegative.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV N<jats:sub>CORE<\/jats:sub>. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2022-000271","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:50:23Z","timestamp":1658973023000},"page":"e000271","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-6129","authenticated-orcid":false,"given":"Linn","family":"Persson Berg","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Longhi","sequence":"additional","affiliation":[{"name":"Lab. Architecture et Fonction des Macromol\u00e9cules Biologiques (AFMB), UMR 7257, Aix Marseille University and Centre National de la Recherche Scientifique (CNRS), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Kockum","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9255","authenticated-orcid":false,"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Thomsson","sequence":"additional","affiliation":[{"name":"Mammalian Protein Expression Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"B\u00e4ckstr\u00f6m","sequence":"additional","affiliation":[{"name":"Mammalian Protein Expression Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fogdell-Hahn","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2025072811361606000_4.2.e000271.1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.6.noc50328"},{"key":"2025072811361606000_4.2.e000271.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21886"},{"key":"2025072811361606000_4.2.e000271.3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2012.03.014","article-title":"Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome","volume":"247","author":"Ahlgren","year":"2012","journal-title":"J Neuroimmunol"},{"key":"2025072811361606000_4.2.e000271.4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2014.06.011","article-title":"Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production","volume":"61","author":"Persson","year":"2014","journal-title":"J Clin Virol"},{"key":"2025072811361606000_4.2.e000271.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8360-4"},{"key":"2025072811361606000_4.2.e000271.6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000621"},{"key":"2025072811361606000_4.2.e000271.7","doi-asserted-by":"crossref","first-page":"3072-3079","DOI":"10.1111\/ene.14961","article-title":"Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control study","volume":"28","author":"Grut","year":"2021","journal-title":"Eur J Neurol"},{"key":"2025072811361606000_4.2.e000271.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6912-4"},{"key":"2025072811361606000_4.2.e000271.9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512449682"},{"key":"2025072811361606000_4.2.e000271.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70267-4"},{"key":"2025072811361606000_4.2.e000271.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-322941"},{"key":"2025072811361606000_4.2.e000271.12","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"2025072811361606000_4.2.e000271.13","doi-asserted-by":"publisher","DOI":"10.1159\/000110248"},{"key":"2025072811361606000_4.2.e000271.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028094"},{"key":"2025072811361606000_4.2.e000271.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181aa29fe"},{"key":"2025072811361606000_4.2.e000271.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03083.x"},{"key":"2025072811361606000_4.2.e000271.17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.msard.2013.12.004","article-title":"Multiple sclerosis therapy and Epstein-Barr virus antibody titres","volume":"3","author":"Raffel","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"2025072811361606000_4.2.e000271.18","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/901312","article-title":"Epstein-Barr virus specific antibody response in multiple sclerosis patients during 21 months of natalizumab treatment","volume":"2015","author":"Castellazzi","year":"2015","journal-title":"Dis Markers"},{"key":"2025072811361606000_4.2.e000271.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71283-5","article-title":"Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab","volume":"10","author":"Dominguez-Mozo","year":"2020","journal-title":"Sci Rep"},{"key":"2025072811361606000_4.2.e000271.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2025072811361606000_4.2.e000271.21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12130"},{"key":"2025072811361606000_4.2.e000271.22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025072811361606000_4.2.e000271.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"2025072811361606000_4.2.e000271.24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.wneu.2017.09.131","article-title":"Natalizumab-Associated primary central nervous system lymphoma","volume":"109","author":"Nixon","year":"2018","journal-title":"World Neurosurg"},{"key":"2025072811361606000_4.2.e000271.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit376"},{"key":"2025072811361606000_4.2.e000271.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304332"},{"key":"2025072811361606000_4.2.e000271.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.04.014"},{"key":"2025072811361606000_4.2.e000271.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407320101"},{"key":"2025072811361606000_4.2.e000271.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.9.5307"},{"key":"2025072811361606000_4.2.e000271.30","doi-asserted-by":"crossref","first-page":"e01562","DOI":"10.1128\/JVI.01562-16","article-title":"High Epstein-Barr virus load and genomic diversity are associated with generation of gp350-Specific neutralizing antibodies following acute infectious mononucleosis","volume":"91","author":"Weiss","year":"2017","journal-title":"J Virol"},{"key":"2025072811361606000_4.2.e000271.31","doi-asserted-by":"publisher","DOI":"10.1086\/523813"},{"key":"2025072811361606000_4.2.e000271.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2020.113927","article-title":"Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen","volume":"284","author":"Persson Berg","year":"2020","journal-title":"J Virol Methods"},{"key":"2025072811361606000_4.2.e000271.33","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394701"},{"key":"2025072811361606000_4.2.e000271.34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10072-010-0345-y","article-title":"Swedish natalizumab (Tysabri) multiple sclerosis surveillance study","volume":"31 Suppl 3","author":"Piehl","year":"2011","journal-title":"Neurol Sci"},{"key":"2025072811361606000_4.2.e000271.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103288","article-title":"Follow-Up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosis","volume":"56","author":"Jons","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2025072811361606000_4.2.e000271.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066092"},{"key":"2025072811361606000_4.2.e000271.37","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001030","article-title":"Effects of natalizumab therapy on intrathecal immunoglobulin G production indicate targeting of Plasmablasts","volume":"8","author":"Schl\u00fcter","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072811361606000_4.2.e000271.38","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513477229"},{"key":"2025072811361606000_4.2.e000271.39","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514556296"},{"key":"2025072811361606000_4.2.e000271.40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600944"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2022-000271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:36:25Z","timestamp":1753727785000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2022-000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjno-2022-000271"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2022-000271","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}